TY - JOUR T1 - CD64 and CD169 could help differentiate bacterial from viral infections in Emergency Department JF - medRxiv DO - 10.1101/2020.10.28.20221259 SP - 2020.10.28.20221259 AU - Pénélope Bourgoin AU - Thomas Soliveres AU - Alexandra Barbaresi AU - Anderson Loundou AU - Isabelle Arnoux AU - Denis Bernot AU - Pierre-Emmanuel Morange AU - Pierre Michelet AU - Fabrice Malergue AU - Thibaut Markarian Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20221259.abstract N2 - Background The identification of a bacterial, viral or even non-infectious cause is essential in the management of febrile syndrome in the emergency department (ED) setting, especially in epidemic contexts such as flu or CoVID-19.Objectives The aim of this study was to assess discriminative performances of two biomarkers, CD64 on neutrophils (nCD64) and CD169 on monocytes (mCD169), using a new flow cytometry procedure, in patients presenting with fever to the ED. Human leucocyte antigen-DR on monocytes (mHLA-DR), HLA-ABC ratio (rHLA-ABC), and CD64 on monocytes (mCD64) were also assessed.Methods 85 adult patients presenting with potential infection were included during the 2019 flu season in the ED of La Timone Hospital. They were divided into four diagnostic outcomes according to their clinical records: no-infection, bacterial infection, viral infection and co-infection.Results mCD169 was elevated in patients suffering from Flu A virus or Respiratory Syncytial Virus, while nCD64 was mainly found elevated in subjects with Streptococcus pneumoniae. In total, 38 (45%) patients were diagnosed with bacterial infections, 11 (13%) with viral infections and 29 (34%) with co-infections. nCD64 and mCD169 showed 90% and 80% sensitivity, and 78% and 91% specificity, respectively, for identifying patients with bacterial or viral infections. Other biomarkers had lower discriminative performances.Conclusions nCD64 and mCD169 have potential for accurately distinguishing bacterial and acute viral infections. Combined in an easy and rapid flow cytometry procedure, they constitute a potential improvement for infection management in the ED setting, and could even help for the triage of patients during emerging epidemics.Competing Interest StatementFabrice Malergue and Penelope Bourgoin are Beckman Coulter employees. The other authors declare no competing interest.Clinical TrialNCT03912870Funding StatementPenelope Bourgoin is recipient of a CIFRE PhD grant (2016/1368) from the ANRT (National Agency for Research and Technology). This study was partially supported by Beckman Coulter through donations of the research reagents used in the study and participation of the two employees mentioned above. This private company had no role in the study design, or collection and interpretation of the clinical data. Beckman Coulter and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States of America and other countries. All other trademarks are the property of their respective owners. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This observational and noninterventional prospective study was approved by the La Timone Hospital Ethical Committee and the Committee for Protection of Persons (CPP approval no. 181160; ID-RCB approval no. 2018 A02706-49).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors certify that this manuscript reports original clinical research data. Individual data that underlie the results reported in this article are available from the corresponding author following publication, including the study report and study protocol. Additional data are available upon reasonable request. ER -